A Phase 3 interventional study of Semaglutide and Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 33rd largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 67th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 64th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 62 in phase 3, and was the 110th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 242 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants with T2D at screening:
- Diagnosed with T2D greater than or equal to 180 days prior to the day of screening
Treated with either:
Exclusion Criteria:
For participants without T2D at screening:
- greater than or equal to 6.5percent (48 mmol/mol) as measured by the laboratory.
For participants with T2D at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.
Drug: Semaglutide
Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.
Drug: Placebo
Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
Change in Body Weight (%)
Percentage change in body weight from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.
Time frame: At end of treatment (week 44)
Number of Participants Who Achieved Body Weight Reduction ≥ 10% (Yes/No)
Number of participants who achieved ≥10% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.
Time frame: At end of treatment (week 44)
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Body Weight (kg)
Change in body weight in kilogram (kg) from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Body Mass Index
Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Waist-height Ratio (WtHR)
Change in waist-height ratio (WtHR) from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Diastolic Blood Pressure
Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Total Cholesterol (mmol/L) - Ratio to Baseline
Change in total cholesterol measured in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline
Change in high density lipoprotein (HDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline
Change in low density lipoprotein (LDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline
Change in VLDL cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Triglycerides (mmol/L) - Ratio to Baseline
Change in triglycerides measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline
Change in free fatty acids measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline
Change in high sensitivity C-Reactive Protein (hsCRP) measured in milligram per litre (mg/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in HbA1c (%)
Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in HbA1c (mmol/Mol)
Change in HbA1c measured in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Fasting Plasma Glucose (mg/dL)
Change in fasting plasma glucose (FPG) measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Change in Fasting Plasma Glucose (mmol/L)
Change in FPG measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Number of Treatment Emergent Adverse Events (TEAEs)
Number of TEAEs from baseline (week 0) to end of study (week 49) is presented. An adverse event is any untoward medical occurrence in a clinical trial participant that is temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.
Time frame: From baseline (week 0) to end of study (week 49)
Number of Serious Adverse Events (SAEs)
Number of SAEs from baseline (week 0) to end of study (week 49) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.
Time frame: From baseline (week 0) to end of study (week 49)
Change in Pulse
Change in pulse from baseline (week 0) to end of treatment (week 44) is presented.
Time frame: Baseline (week 0), end of treatment (week 44)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L) confirmed by BG meter for participants with T2D from baseline (week 0) to end of study (week 49) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than 3.0 mmol/L (54 mg/dL) confirmed by BG meter.
Time frame: From baseline (week 0) to end of study (week 49)
The trial was conducted at 19 sites across mainland China and Taiwan.
| Milestone | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Started | 161 | 81 |
| Full analysis set | 161 | 81 |
| Safety analysis set | 161 | 81 |
| Completed | 161 | 79 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Percentage change in body weight from baseline (week 0) to end of treatment (week 44) is presented.
| Percentage change in body weight | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Body Weight (%) | -12.2 ± 8.2 | -2.2 ± 5.4 |
Number of participants who achieved ≥5% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 5% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 5% weight reduction.
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 128 | 19 |
| No | 31 | 59 |
Number of participants who achieved ≥10% body weight reduction at the end of treatment (week 44) is presented. In the reported data, 'Yes' infers the number of participants who have achieved greater than or equal to 10% weight reduction, whereas 'No' infers the number of participants who have not achieved greater than or equal to 10% weight reduction.
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 96 | 9 |
| No | 63 | 69 |
Change in waist circumference from baseline (week 0) to end of treatment (week 44) is presented.
| Centimeter (cm) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Waist Circumference | -9.1 ± 6.2 | -2.4 ± 5.0 |
Change in body weight in kilogram (kg) from baseline (week 0) to end of treatment (week 44) is presented.
| Kg | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Body Weight (kg) | -9.3 ± 6.1 | -1.7 ± 4.3 |
Change in body mass index from baseline (week 0) to end of treatment (week 44) is presented.
| Kilogram per square meter (kg/m^2) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Body Mass Index | -3.4 ± 2.3 | -0.6 ± 1.5 |
Change in waist-height ratio (WtHR) from baseline (week 0) to end of treatment (week 44) is presented.
| Ratio of waist-height | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Waist-height Ratio (WtHR) | -0.05 ± 0.04 | -0.01 ± 0.03 |
Change in systolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented.
| Millimeter of mercury (mmHg) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -7 ± 13 | -4 ± 10 |
Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 44) is presented
| mmHg | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure | -4 ± 9 | -2 ± 8 |
Change in total cholesterol measured in millimoles per liter (mmol/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of total cholesterol | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Total Cholesterol (mmol/L) - Ratio to Baseline | 0.94 ± 16.5 | 1.01 ± 13.1 |
Change in high density lipoprotein (HDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of HDL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline | 1.04 ± 13.8 | 1.06 ± 13.7 |
Change in low density lipoprotein (LDL) cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of LDL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline | 0.97 ± 24.4 | 1.02 ± 24.1 |
Change in VLDL cholesterol measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of VLDL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Very Low-Density Lipoproteins (VLDL) Cholesterol (mmol/L) - Ratio to Baseline | 0.72 ± 44.2 | 0.93 ± 38.8 |
Change in triglycerides measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of triglycerides | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Triglycerides (mmol/L) - Ratio to Baseline | 0.71 ± 46.5 | 0.91 ± 44.5 |
Change in free fatty acids measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of free fatty acids | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Free Fatty Acids (mmol/L) - Ratio to Baseline | 0.88 ± 60.2 | 0.99 ± 61.5 |
Change in high sensitivity C-Reactive Protein (hsCRP) measured in milligram per litre (mg/L) from baseline (week 0) to end of treatment (week 44) is presented as ratio to baseline.
| Ratio of hsCRP | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline | 0.69 ± 154.3 | 0.68 ± 118.2 |
Change in glycosylated haemoglobin (HbA1c) in percentage from baseline (week 0) to end of treatment (week 44) is presented.
| Percentage of HbA1c | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in HbA1c (%) | -0.4 ± 0.5 | 0.0 ± 0.3 |
Change in HbA1c measured in millimoles per mole (mmol/mol) from baseline (week 0) to end of treatment (week 44) is presented.
| mmol/mol | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in HbA1c (mmol/Mol) | -4.2 ± 5.9 | 0.5 ± 3.6 |
Change in fasting plasma glucose (FPG) measured in milligrams per deciliter (mg/dL) from baseline (week 0) to end of treatment (week 44) is presented.
| mg/dL | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Fasting Plasma Glucose (mg/dL) | -12.3 ± 18.4 | 0.5 ± 14.5 |
Change in FPG measured in mmol/L from baseline (week 0) to end of treatment (week 44) is presented.
| mmol/L | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Fasting Plasma Glucose (mmol/L) | -0.7 ± 1.0 | 0.0 ± 0.8 |
Number of TEAEs from baseline (week 0) to end of study (week 49) is presented. An adverse event is any untoward medical occurrence in a clinical trial participant that is temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.
| Events | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 614 | 183 |
Number of SAEs from baseline (week 0) to end of study (week 49) is presented. A serious adverse event (SAE) is any untoward medical occurrence that fulfils at least one of following criteria: results in death; is life-threatening; requires inpatient or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect; important medical event.
| Events | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Serious Adverse Events (SAEs) | 14 | 3 |
Change in pulse from baseline (week 0) to end of treatment (week 44) is presented.
| Beats per minute (Beats/min) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Pulse | 3 ± 11 | 1 ± 9 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L) confirmed by BG meter for participants with T2D from baseline (week 0) to end of study (week 49) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than 3.0 mmol/L (54 mg/dL) confirmed by BG meter.
| Episodes | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) Less Than (<) 3.0 mmol/L Confirmed by Blood Glucose (BG) Meter - Participants With Type 2 Diabetes (T2D) | 1 | 0 |
Collected over From baseline (week 0) to end of study (week 49). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sema 2.4 mg | 0/161 (0%) | 13/161 (8.1%) | 113/161 (70.2%) |
| Placebo | 0/81 (0%) | 3/81 (3.7%) | 26/81 (32.1%) |
| Event | Sema 2.4 mg | Placebo |
|---|---|---|
| Angina unstableCardiac disorders | 0/161 | 1/81 |
| Patellofemoral pain syndromeMusculoskeletal and connective tissue disorders | 0/161 | 1/81 |
| Pyelonephritis acuteInfections and infestations | 0/161 | 1/81 |
| Abdominal painGastrointestinal disorders | 1/161 | 0/81 |
| CholecystitisHepatobiliary disorders | 1/161 | 0/81 |
| CholelithiasisHepatobiliary disorders | 1/161 | 0/81 |
| Clavicle fractureInjury, poisoning and procedural complications | 1/161 | 0/81 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/161 | 0/81 |
| Endometrial hyperplasiaReproductive system and breast disorders | 1/161 | 0/81 |
| HydronephrosisRenal and urinary disorders | 1/161 | 0/81 |
| Event | Sema 2.4 mg | Placebo |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 31/161 | 2/81 |
| DiarrhoeaGastrointestinal disorders | 30/161 | 6/81 |
| NauseaGastrointestinal disorders | 29/161 | 2/81 |
| Upper respiratory tract infectionInfections and infestations | 28/161 | 12/81 |
| ConstipationGastrointestinal disorders | 22/161 | 3/81 |
| NasopharyngitisInfections and infestations | 16/161 | 2/81 |
| VomitingGastrointestinal disorders | 16/161 | 0/81 |
| Abdominal distensionGastrointestinal disorders | 13/161 | 1/81 |
| DizzinessNervous system disorders | 13/161 | 2/81 |
| DyspepsiaGastrointestinal disorders | 13/161 | 0/81 |
Full analysis set (FAS) included all randomised participants.
| Age, Continuous(Years) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 42 ± 10 | 41 ± 12 | 41 ± 11 |
| Sex: Female, Male(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Female | 79 | 42 | 121 |
| Male | 82 | 39 | 121 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 161 | 81 | 242 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 161 | 81 | 242 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Sep 2023 to primary completion in Apr 2025, 18 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide